FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385954742> ?p ?o ?g. }

• W4385954742 endingPage "350" @default.
• W4385954742 startingPage "350" @default.
• W4385954742 abstract "<ns4:p><ns4:bold>Background: </ns4:bold>Given the low levels of coronavirus disease 2019 (COVID-19) vaccine coverage in sub-Saharan Africa (sSA), despite high levels of natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) exposures, strategies for extending the breadth and longevity of naturally acquired immunity are warranted. Designing such strategies will require a good understanding of natural immunity.<ns4:bold> </ns4:bold></ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>We measured whole-spike immunoglobulin G (IgG) and spike-receptor binding domain (RBD) total immunoglobulins (Igs) on 585 plasma samples collected longitudinally over five successive time points within six months of COVID-19 diagnosis in 309 COVID-19 patients. We measured antibody-neutralising potency against the wild-type (Wuhan) SARS-CoV-2 pseudovirus in a subset of 51 patients over three successive time points. Binding and neutralising antibody levels and potencies were then tested for correlations with COVID-19 severities.</ns4:p><ns4:p> <ns4:bold>Results: </ns4:bold>Rates of seroconversion increased from day 0 (day of PCR testing) to day 180 (six months)<ns4:bold> </ns4:bold>(63.6% to 100 %) and (69.3 % to 97%) for anti-spike-IgG and anti-spike-RBD binding Igs, respectively. Levels of these binding antibodies peaked at day 28 (p<0.0001) and were subsequently maintained for six months without significant decay (p>0.99). Similarly, antibody-neutralising potencies peaked at day 28 (p<0.0001) but declined by three-fold, six months after COVID-19 diagnosis (p<0.0001). Binding antibody levels were highly correlated with neutralising<ns4:sub> </ns4:sub>antibody potencies at all the time points analysed (r>0.6, p<0.0001). Levels and potencies of binding and neutralising antibodies increased with disease severity.</ns4:p><ns4:p> <ns4:bold>Conclusions: </ns4:bold>Most COVID-19 patients generated SARS-CoV-2 specific binding antibodies that remained stable in the first six months of infection. However, the respective neutralising antibodies decayed three-fold by month-six of COVID-19 diagnosis suggesting that they are short-lived, consistent with what has been observed elsewhere in the world. Thus, regular vaccination boosters are required to sustain the high levels of anti-SARS-CoV-2 naturally acquired neutralising antibody potencies in our population.</ns4:p>" @default.
• W4385954742 created "2023-08-18" @default.
• W4385954742 creator A5004083701 @default.
• W4385954742 creator A5004422641 @default.
• W4385954742 creator A5009075899 @default.
• W4385954742 creator A5012355329 @default.
• W4385954742 creator A5012731669 @default.
• W4385954742 creator A5013961861 @default.
• W4385954742 creator A5019859396 @default.
• W4385954742 creator A5023271677 @default.
• W4385954742 creator A5024554546 @default.
• W4385954742 creator A5029161007 @default.
• W4385954742 creator A5033026770 @default.
• W4385954742 creator A5037073910 @default.
• W4385954742 creator A5040183990 @default.
• W4385954742 creator A5048121336 @default.
• W4385954742 creator A5048950576 @default.
• W4385954742 creator A5051553404 @default.
• W4385954742 creator A5056793536 @default.
• W4385954742 creator A5057605175 @default.
• W4385954742 creator A5069550281 @default.
• W4385954742 creator A5069750974 @default.
• W4385954742 creator A5069992901 @default.
• W4385954742 creator A5072290618 @default.
• W4385954742 creator A5073485372 @default.
• W4385954742 creator A5074613230 @default.
• W4385954742 creator A5080540974 @default.
• W4385954742 creator A5083853693 @default.
• W4385954742 creator A5087541775 @default.
• W4385954742 creator A5089192522 @default.
• W4385954742 date "2023-08-17" @default.
• W4385954742 modified "2023-10-14" @default.
• W4385954742 title "Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study" @default.
• W4385954742 cites W1007053 @default.
• W4385954742 cites W1621402431 @default.
• W4385954742 cites W1996710470 @default.
• W4385954742 cites W2112011162 @default.
• W4385954742 cites W2160358721 @default.
• W4385954742 cites W3014721277 @default.
• W4385954742 cites W3021590963 @default.
• W4385954742 cites W3027910545 @default.
• W4385954742 cites W3030005872 @default.
• W4385954742 cites W3033622610 @default.
• W4385954742 cites W3038435002 @default.
• W4385954742 cites W3038698073 @default.
• W4385954742 cites W3038707046 @default.
• W4385954742 cites W3041099309 @default.
• W4385954742 cites W3080581616 @default.
• W4385954742 cites W3082342835 @default.
• W4385954742 cites W3084541934 @default.
• W4385954742 cites W3086125063 @default.
• W4385954742 cites W3086192834 @default.
• W4385954742 cites W3091073871 @default.
• W4385954742 cites W3091214020 @default.
• W4385954742 cites W3091903377 @default.
• W4385954742 cites W3092004707 @default.
• W4385954742 cites W3092033637 @default.
• W4385954742 cites W3092301564 @default.
• W4385954742 cites W3092794099 @default.
• W4385954742 cites W3092801527 @default.
• W4385954742 cites W3093231763 @default.
• W4385954742 cites W3093667122 @default.
• W4385954742 cites W3094968263 @default.
• W4385954742 cites W3096786678 @default.
• W4385954742 cites W3104471981 @default.
• W4385954742 cites W3113228067 @default.
• W4385954742 cites W3113441434 @default.
• W4385954742 cites W3118121970 @default.
• W4385954742 cites W3121008609 @default.
• W4385954742 cites W3121906900 @default.
• W4385954742 cites W3122043911 @default.
• W4385954742 cites W3126944781 @default.
• W4385954742 cites W3132743282 @default.
• W4385954742 cites W3134045730 @default.
• W4385954742 cites W3148277587 @default.
• W4385954742 cites W3153715095 @default.
• W4385954742 cites W3154381322 @default.
• W4385954742 cites W3158384824 @default.
• W4385954742 cites W3165046644 @default.
• W4385954742 cites W3167555428 @default.
• W4385954742 cites W3168369230 @default.
• W4385954742 cites W3172858351 @default.
• W4385954742 cites W3176440618 @default.
• W4385954742 cites W3179365271 @default.
• W4385954742 cites W3196823670 @default.
• W4385954742 cites W3197511077 @default.
• W4385954742 cites W3213594134 @default.
• W4385954742 cites W3217671074 @default.
• W4385954742 cites W4212918871 @default.
• W4385954742 cites W4213243854 @default.
• W4385954742 cites W4220716904 @default.
• W4385954742 cites W4221034841 @default.
• W4385954742 cites W4312067520 @default.
• W4385954742 doi "https://doi.org/10.12688/wellcomeopenres.19414.1" @default.
• W4385954742 hasPublicationYear "2023" @default.
• W4385954742 type Work @default.
• W4385954742 citedByCount "0" @default.
• W4385954742 crossrefType "journal-article" @default.

• next